Research and development of novel modified tissue-type plasminogen- activator (t-PA), Pamiteplase

Folia Pharmacologica Japonica

Volumn 115, Issue 4, 2000, Pages 237-243

  Katoh, Masao ^a   Hayamizu, Kouki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Acute myocardial infarction; Modified t PA; Thrombolysis; Tissue type plasminogen activator

Indexed keywords

DRUG ANTIBODY; FIBRIN; PAMITEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ANTIBODY PRODUCTION; BLEEDING; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; FIBRINOLYSIS; HEART MUSCLE REPERFUSION; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 0034072575     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.115.237     Document Type: Review

References (22)

1. Rentrop KP, Klanke H, Karsch KR, Wiegand V, Kostering H, Oster H and Leitz K: Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2, 354-363 (1979)
2. Katoh M, Shimizu Y, Kawauchi Y, Ishida J, Takayama M, Yokota M, Yano E, Kawasaki T, Katsuta K, Yano S, et al: Comparison of clearance rate of various tissue plasminogen activator (t-PA) analogues. Thromb Haemost 62, 542 (1989)
3. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heynecker HL and Vehar GA: Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen as assessed by site-directed mutagenesis. Biochemistry 26, 338-343 (1987)
4. Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N and Kawai C: Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis. Jpn Circ J 51, 431-435 (1987)
5. Kawasaki T, Katoh M, Kaku S, Gushima H, Takanaka T, Yui K and Kawai C: Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 63, 9-16 (1993)
6. Kawasaki T, Katoh M, Kaku S, Gushima H, Takanaka T, Yui K and Kawai C: Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 63, 319-325 (1993)
7. Suzuki M, Funatsu T, Tanaka H and Usuda S: YM 866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi. Jpn J Pharmacol 77, 177-183 (1998)
8. Kawasaki T, Kaku S, Sakai Y and Takanaka T: Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis. J Pharm Pharmacol 48, 1041-1048 (1996)
9. Kawasaki T, Kawamura S, Katoh S and Takenaka T: Experimental model of carotide artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Jpn J Pharmacol 63, 133-142 (1993)
10. Kawasaki T, Kaku S, Takenaka T, Yanagi K and Ohshima N: Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model. J Cardiovasc Pharmacol 23, 884-889 (1994)
11. Ishikawa A, Fujiwara M, Ohata H, Wakata A, Hoshino K, Matsuzawa T, Barrow PC, Shimazu H, Ono C, Putman DL, et al: Reproductive toxicity, mutagenicity and antigenicity of pamiteplase (genetical recombination). J Toxicol Sci 22, 207-217 (1997)
12. Ross R: Plasminogen Activator and Angioplasty Compatibility Trial (PACT). Am Heart J 135, 1103-1104 (1998)